The Latest Breaking News from Novo

Viking Therapeutics reported strong weight loss for higher doses of its experimental obesity drug.

Novo Nordisk has lost about a quarter of its value since the end of June. Meanwhile, indications are that its diabetes and weight-loss drugs may be useful in fighting cardiovascular disease, arthritis, opioid and alcohol addiction, and Alzheimer's. Novo remains a leader in the sector, and is trading at a…

Novo Nordisk stock tumbled Friday — pulling Corbus into a steep dive — after its new obesity drug caused neuropsychiatric side effects.

As surprise pregnancies multiply, some scientists are investigating whether weight loss drugs can improve fertility in women with polycystic ovary syndrome

Weight-loss drug kingpins Eli Lilly and Novo Nordisk could join the trillion-dollar company club before even Tesla, according to a report.

The weight-loss drugs market could be worth up to $144 billion within six years. And a bevy of pharma stocks could get a lift.

Monday's global sell-off turned into a stock market rally attempt. Palantir, Eli Lilly and Fortinet were among the earnings winners.

As Congress pushes for Medicare to cover anti-obesity drugs, puzzlement remains about who should get them, for how long, and at what price.

Novo Nordisk stock tumbled Wednesday after the drugmaker reported a rare sales miss for its two biggest moneymakers, Ozempic and Wegovy.